Approval · Notice of Compliance 14883 · 2013
ZOLINZA: Notice of Compliance 14883
Issued October 25, 2013
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 14883
- Date
- October 25, 2013
- Company
- Merck Canada IncKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the product monograph based on new information regarding the administration of vorinostat to patients with hepatic impairment or patients recovering from surgery to the bowel
- Therapeutic class
- Histone deacetylase inhibitor; antineoplastic agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ZOLINZA | Not yet assigned | — |
Medicinal ingredients
- VORINOSTAT 100 MG per CAP